Weight loss research questions need for GLP-1 drugs
A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are GLP-1s actually needed to achieve weight loss?
Apr 17, 2026
0
34
Amino Acid, Peptide, or Protein: Gastric Inhibitory Polypeptide
Medical news and research articles
Weight loss drug linked to lower risk of eye disease in patients with diabetes
The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. ...
Feb 11, 2026
0
8
Zepbound outperforms Wegovy in head-to-head weight loss study
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy.
May 12, 2025
0
33
Voyages into the small intestine shed new light on ways to improve gut health
Microbiome research to date has been much like the parable of the blind men and the elephant. How much can be said about an elephant by examining just its tail? Researchers have studied what is most readily available—stool ...
Jun 17, 2024
0
40
Your body has a built-in system that works like weight loss meds: Food and your gut microbiome
Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news. They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for ...
Jan 17, 2024
0
77
New weight-loss drug Zepbound is now available, company says
The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday.
Dec 6, 2023
0
105
Mounjaro has been authorized for weight loss in the UK—here's how it compares to Wegovy
The type 2 diabetes drug tirzepatide (better known by its brand name Mounjaro) has recently been authorized by the UK's medicines regulation authority for use in weight loss and weight management. The decision was made on ...
Nov 15, 2023
0
116
